Skip to main content

Idiopathic Pulmonary Fibrosis

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
NCT05130970 | Phase 2 | Interventional

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).

Trial Information
46 Sites
80 Participants
40 Years

If interested, contact for more information

The University of Alabama at Birmingham
Birmingham,Alabama,United States,35205
Pulmonary Associates Clinical Trials AZ
Phoenix,Arizona,United States,85032
National Institute of Clinical Research
Huntington Beach,California,United States,92647
University of Southern California Center for Advanced Lung Disease
Los Angeles,California,United States,90033
University of California Irvine
Orange,California,United States,92868
Meris Clinical Research
Brandon,Florida,United States,33511
Lakes Research
Miami Lakes,Florida,United States,33014
Reliant Medical Research
Miami,Florida,United States,33165
US Associates in Research LLC
Miami,Florida,United States,33175
Renstar Medical Research
Ocala,Florida,United States,34471
Central Florida Pulmonary Group, PA
Orlando,Florida,United States,32803
University of Kansas Medical Center
Kansas City,Kansas,United States,66160
Jadestone Clinical Research
Silver Spring,Maryland,United States,20904
Hannibal Clinic
Hannibal,Missouri,United States,63401
Weill Cornell Medical Center
New York,New York,United States,10021
Superior Clinical Research
Smithfield,North Carolina,United States,27577
Southeastern Research Center
Winston-Salem,North Carolina,United States,27103
University of Cincinnati
Cincinnati,Ohio,United States,45267
University of Oklahoma Health Sciences Center
Oklahoma City,Oklahoma,United States,73104
Temple University TMS
Philadelphia,Pennsylvania,United States,19140
Clinical Trial Center of Middle Tennesse
Franklin,Tennessee,United States,37067
Elite Medical Research
Dallas,Texas,United States,75230
Baylor Scott and White Health Advanced Lung Disease Specialists
Dallas,Texas,United States,75246
Baylor College of Medicine
Houston,Texas,United States,77030
Royal Adelaide Hospital
Medizinische Univeritt Graz
Kepler Universittsklinikum
Universitair Ziekenhuis (UZ) Leuven
Centre Hospitalier Universitaire Sart Tilman
St. Joseph's Healthcare Hamilton
Hamilton,Canada,L8N 4A6
Dr. Syed Anees Medicine Professional Corporation
Windsor,Canada,N8X 1T3
Odense Universitetshospital Lungemedicinsk Forskningsenhed
Fachkrankenhaus Coswig GmbH
Universitaetsklinikum Essen Ruhrlandklinik (Westdeutsches Lungenzentrum)
Medizinische Hochschule Hannover Klinik fr Pneumologie
Petrus Krankenhaus Wuppertal
Azienda Ospedaliera Universitaria Ospedali Riuniti Foggia
Centrum Medycyny Oddechowej Bialymstoku
Twoja Przychodnia Centrum Medyczne Nowa Sol
Nowa Sol,Poland,67-100
Centrum Bada Klinicznych NZOZ
Giromed Institute, SLP
Hospital Universitario Puerta del Mar (HUPM)
The Churchill Hospital Oxford University Hospitals NHS Trust
Oxford,United Kingdom,OX3 7LE
Queen Elizabeth Hospital
Birmingham,United Kingdom,B15 2GW
Altnagelvin Area Hospital
Londonderry,United Kingdom,BT47 6SB
Manchester Univ NHS Wythenshawe Hospital
Manchester,United Kingdom,M23 9LT

Study Eligibility Criteria

  • Male or female patients ≥ 40 years of age
  • Documented diagnosis of IPF
  • History of clinically significant cardiovascular disease, including myocardial infarction, unstable ischemic heart disease, congestive heart failure, or angina during the 6 months before screening
  • Sinoatrial or atrioventricular block, uncontrolled hypertension
  • Active bleeding or current clinically significant coagulopathy

Additional Studies

Additional studies can be found at